Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial
详细信息 查看全文
- 作者：Glenn Phillipsa ; Glenn.Phillips@biogen.com" class="auth_mail" title="E-mail the corresponding author ; Shien Guob ; Randall Benderc ; Eva Havrdová ; d ; Irina Proskorovskye ; Timothy Vollmerf
- 关键词：Daclizumab high-yield process ; Relapsing and remitting multiple sclerosis ; MS-specific health-related quality of life measures ; Multiple Sclerosis Impact Scale
- 刊名：Multiple Sclerosis and Related Disorders
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：6
- 期：Complete
- 页码：66-72
- 全文大小：386 K
文摘
- •
Treatment with DAC HYP 150 mg significantly improved HRQoL in patients with RRMS.
- •
This benefit is likely due to reducing the risk of relapse and disability progression.
- •
MS-specific HRQoL measures better capture the treatment effect on HRQoL.